41 related articles for article (PubMed ID: 38529301)
21. IL-6 in inflammation, autoimmunity and cancer.
Hirano T
Int Immunol; 2021 Mar; 33(3):127-148. PubMed ID: 33337480
[TBL] [Abstract][Full Text] [Related]
22. Cytokine profiles in patients with newly diagnosed multiple myeloma: Survival is associated with IL-6 and IL-17A levels.
Gu J; Huang X; Zhang Y; Bao C; Zhou Z; Jin J
Cytokine; 2021 Feb; 138():155358. PubMed ID: 33183958
[TBL] [Abstract][Full Text] [Related]
23. Validation of the Eighth Edition TNM Lung Cancer Staging System.
Hwang JK; Page BJ; Flynn D; Passmore L; McCaul E; Brady J; Yang IA; Marshall H; Windsor M; Bowman RV; Naidoo R; Guan T; Philpot S; Blake ME; Fong KM
J Thorac Oncol; 2020 Apr; 15(4):649-654. PubMed ID: 31863848
[TBL] [Abstract][Full Text] [Related]
24. Low-Dose CT Scan for Lung Cancer Screening: Clinical and Coding Considerations.
Shieh Y; Bohnenkamp M
Chest; 2017 Jul; 152(1):204-209. PubMed ID: 28336485
[TBL] [Abstract][Full Text] [Related]
25. Update on biomarkers for the detection of lung cancer.
Jantus-Lewintre E; Usó M; Sanmartín E; Camps C
Lung Cancer (Auckl); 2012; 3():21-29. PubMed ID: 28210122
[TBL] [Abstract][Full Text] [Related]
26. Microenvironmental changes in the progression from adenocarcinoma in situ to minimally invasive adenocarcinoma and invasive lepidic predominant adenocarcinoma of the lung.
Naito M; Aokage K; Saruwatari K; Hisakane K; Miyoshi T; Hishida T; Yoshida J; Masato S; Kojima M; Kuwata T; Fujii S; Ochiai A; Sato Y; Tsuboi M; Ishii G
Lung Cancer; 2016 Oct; 100():53-62. PubMed ID: 27597281
[TBL] [Abstract][Full Text] [Related]
27. Non-small cell lung cancer: current treatment and future advances.
Zappa C; Mousa SA
Transl Lung Cancer Res; 2016 Jun; 5(3):288-300. PubMed ID: 27413711
[TBL] [Abstract][Full Text] [Related]
28. IL-6 Secreted from Cancer-Associated Fibroblasts Mediates Chemoresistance in NSCLC by Increasing Epithelial-Mesenchymal Transition Signaling.
Shintani Y; Fujiwara A; Kimura T; Kawamura T; Funaki S; Minami M; Okumura M
J Thorac Oncol; 2016 Sep; 11(9):1482-92. PubMed ID: 27287412
[TBL] [Abstract][Full Text] [Related]
29. The IL-6-STAT3 axis mediates a reciprocal crosstalk between cancer-derived mesenchymal stem cells and neutrophils to synergistically prompt gastric cancer progression.
Zhu Q; Zhang X; Zhang L; Li W; Wu H; Yuan X; Mao F; Wang M; Zhu W; Qian H; Xu W
Cell Death Dis; 2014 Jun; 5(6):e1295. PubMed ID: 24946088
[TBL] [Abstract][Full Text] [Related]
30. The prognostic values of CA125, CA19.9, NSE, AND SCC for stage I NSCLC are limited.
Ma S; Shen L; Qian N; Chen K
Cancer Biomark; 2011-2012; 10(3-4):155-62. PubMed ID: 22674301
[TBL] [Abstract][Full Text] [Related]
31. Lung cancers diagnosed at annual CT screening: volume doubling times.
Henschke CI; Yankelevitz DF; Yip R; Reeves AP; Farooqi A; Xu D; Smith JP; Libby DM; Pasmantier MW; Miettinen OS;
Radiology; 2012 May; 263(2):578-83. PubMed ID: 22454506
[TBL] [Abstract][Full Text] [Related]
32. Cancer biomarkers.
Henry NL; Hayes DF
Mol Oncol; 2012 Apr; 6(2):140-6. PubMed ID: 22356776
[TBL] [Abstract][Full Text] [Related]
33. Targeting the interleukin-6/Jak/stat pathway in human malignancies.
Sansone P; Bromberg J
J Clin Oncol; 2012 Mar; 30(9):1005-14. PubMed ID: 22355058
[TBL] [Abstract][Full Text] [Related]
34. Nodular ground-glass opacity at thin-section CT: histologic correlation and evaluation of change at follow-up.
Park CM; Goo JM; Lee HJ; Lee CH; Chun EJ; Im JG
Radiographics; 2007; 27(2):391-408. PubMed ID: 17374860
[TBL] [Abstract][Full Text] [Related]
35. Elevation of cytokeratin 19 fragment (CYFRA 21-1) in serum of patients with radiation pneumonitis: possible marker of epithelial cell damage.
Fujita J; Ohtsuki Y; Bandoh S; Takashima H; Ueda Y; Wu F; Tojo Y; Kubo A; Ishida T
Respir Med; 2004 Apr; 98(4):294-300. PubMed ID: 15072169
[TBL] [Abstract][Full Text] [Related]
36. Interleukin-6 promotes cervical tumor growth by VEGF-dependent angiogenesis via a STAT3 pathway.
Wei LH; Kuo ML; Chen CA; Chou CH; Lai KB; Lee CN; Hsieh CY
Oncogene; 2003 Mar; 22(10):1517-27. PubMed ID: 12629515
[TBL] [Abstract][Full Text] [Related]
37. Tumor-related leukocytosis is linked with poor prognosis in patients with lung carcinoma.
Kasuga I; Makino S; Kiyokawa H; Katoh H; Ebihara Y; Ohyashiki K
Cancer; 2001 Nov; 92(9):2399-405. PubMed ID: 11745296
[TBL] [Abstract][Full Text] [Related]
38. CEA, CYFRA21-1 and SCC in non-small cell lung cancer.
Moro D; Villemain D; Vuillez JP; Delord CA; Brambilla C
Lung Cancer; 1995 Oct; 13(2):169-76. PubMed ID: 8581396
[TBL] [Abstract][Full Text] [Related]
39. Serum levels of interleukin 6 in patients with lung cancer.
Yanagawa H; Sone S; Takahashi Y; Haku T; Yano S; Shinohara T; Ogura T
Br J Cancer; 1995 May; 71(5):1095-8. PubMed ID: 7734307
[TBL] [Abstract][Full Text] [Related]
40. Serum levels of interleukin 6, a potent myeloma cell growth factor, as a reflect of disease severity in plasma cell dyscrasias.
Bataille R; Jourdan M; Zhang XG; Klein B
J Clin Invest; 1989 Dec; 84(6):2008-11. PubMed ID: 2592570
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
